Simone Liguori

Simone Liguori

Auto-generated profile, based on publicly available information

Simone Liguori

Department of Neuroscience, Reproductive Sciences and Dentistry, University of Naples Federico II, Naples, Italy

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2026 in Oral Diseases
Verified
Journal Article
Open access
SLSimone Liguori
Simone Liguori
NCNoemi Coppola
Noemi Coppola
ERElvira Ruoppo
Elvira Ruoppo
Federica CanforaFederica Canfora
Federica Canfora
GMGabriele Mignogna
Gabriele Mignogna
SLStefania Leuci
Stefania Leuci
Objective: This study evaluated the CD4 + T‐cell role in mediating post‐Rituximab Pemphigus vulgaris (PV) relapse, comparing CD4 + count and CD4 + /CD20 + ratio between patients who achieved remission and those who relapsed. Methods: The clinical course of 27 PV patients treated with Rituximab was evaluated after a 32‐month median follow‐up. CD4 + and CD20 + counts and CD4 + /CD20 + ratio were longitudinally collected at treatment start date (T0), at 2‐month intervals after Rituximab, until B‐cell repopulation, at B‐cell repopulation, at 6‐, 12‐, and 24‐month intervals after repopulation, and at the end of follow‐up or at relapse. Results: Patients were administered Rituximab as adjuvant therapy: 16 (59%) relapsed while 11 (41%) achieved clinical remission. Higher CD4 + count ( p = 0.02*) and CD4 + /CD20 + ratio ( p = 0.004**) were found at B‐cell repopulation in patients experiencing remission. Moreover, a significant difference ( p = 0.002**) in post‐repopulation CD4 + T‐cell course was found between groups, with patients in clinical remission reporting a mean decrease of 233.5 cells/μL during follow‐up and relapsing patients experiencing a mean increase of 539.4 cells/μL and reaching the maximum CD4 + value at relapse. Conclusions: Lower CD4 + T‐cell value at repopulation and increasing post‐repopulation CD4 + T‐cell count were predictive of disease relapse suggesting a time‐dependent role of CD4 + T cells in post‐Rituximab PV reactivation.

30 September 2026 in Oral Diseases
Verified
Journal Article
Open access
PDF file
DADaniela Adamo
Daniela Adamo
Gennaro MusellaGennaro Musella
Gennaro Musella
Federica CanforaFederica Canfora
Federica Canfora
ECElena Calabria
Elena Calabria
SLSimone Liguori
Simone Liguori
SMSIPMO (Italian Society of Oral Pathology and Medicine)
SIPMO (Italian Society of Oral Pathology and Medicine)
Objective: To assess the psychometric performance of the Hamilton Anxiety Rating Scale (HAM‐A) and Hamilton Depression Rating Scale (HAM‐D) in patients with oral lichen planus (OLP) according to clinical phenotype. Methods: This multicenter SIPMO case–control study included 395 participants: 132 patients with keratotic OLP (K‐OLP), 131 with non‐keratotic OLP (NK‐OLP), and 132 healthy controls (HCs). Internal consistency was assessed with Cronbach's alpha and item discrimination with item–total correlations. HAM‐A and HAM‐D scores were compared between OLP patients and HCs; phenotype‐specific hierarchical regressions identified variables associated with anxiety and depressive symptoms. Results: HAM‐A and HAM‐D showed satisfactory internal consistency in K‐OLP and NK‐OLP patients (HAM‐A α = 0.877 and 0.858; HAM‐D α = 0.768 and 0.766, respectively). Patients with OLP had significantly higher HAM‐A and HAM‐D scores than age‐ and sex‐matched controls without oral mucosal disease ( p = 0.018 and p = 0.002, respectively). The strongest item–total correlations involved depressed mood, tension, insomnia, and somatic symptoms. Poor sleep quality was independently associated with psychological burden, and pain intensity independently predicted anxiety severity in NK‐OLP patients. Conclusions: HAM‐A and HAM‐D showed satisfactory psychometric performance in OLP and may support psychological assessment. Somatic and sleep‐related symptoms were closely associated with psychological distress.

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
SLSimone Liguori
Simone Liguori
FDFrancesca D’ELia
Francesca D’ELia
DDDario Didona
Dario Didona
NCNoemi Coppola
Noemi Coppola
DADaniela Adamo
Daniela Adamo
Stefania LeuciStefania Leuci
Stefania Leuci
Rituximab (RTX) has significantly improved pemphigus vulgaris (PV) management. Nonetheless, the risk of post‐RTX flare is high. This study aimed to identify clinical, serological, and immunological predictors of relapse (R) after RTX therapy. Forty‐four PV patients treated with RTX were enrolled. Baseline clinical characteristics were collected, and anti‐Dsg antibodies levels were evaluated before and after therapy. Peripheral blood flowcytometry was used to assess CD20+ and CD4+ cell frequencies at baseline, at 3‐month intervals until B‐cell repopulation, at B‐cell repopulation time, at 6 and 12 months after repopulation, and at the end of follow‐up or at R. Relapsing patients reported lower levels of CD4+ cells at B‐cell repopulation time and increasing postrepopulation T‐cell values compared to patients experiencing remission. Post‐RTX T‐cell course was found to correlate with anti‐Dsg antibodies titers with the maximum increase of anti‐Dsg3 value coinciding with the peak in CD4+ T‐cell frequency. Additionally, patients initially responding to conventional immunosuppressants reported higher CD4+ T‐cell levels both at baseline and at B‐cell repopulation time and a significantly lower risk of post‐RTX R. Post‐RTX CD4+ T‐cell values were found to predict patients’ clinical response and to correlate with autoantibodies levels. Flowcytometric T‐cell immunophenotyping could be proposed as an additional prognostic marker.